Search Results - john+cardellina

4 Results

Sort By:

Clonal Spodoptera Frugiperda Cell lines for Enhanced Expression

This technology includes Spodoptera frugiperda (Sf9) cells which were developed to produce recombinant adeno-associated virus. The cells maintain a copy of the vector genome and for production, require infection with a single baculovirus that expresses either structural and nonstructural proteins to produce rAAV, or the non-structural (Rep) proteins...

Published: 8/12/2024 | Inventor(s): Lina Li, Robert Kotin

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Licensing, ResearchProducts > Plasmids/Vectors

Sensitizing Cancer Cells to DNA Targeted Therapies

Abstract: Chk2 is a protein kinase activated in response to DNA double strand breaks. In normal tissues, Chk2 phosphorylates and thereby activates substrates that induce programmed cell death, or apoptosis, via interactions with p53, E2F1, PML proteins. In cancer tissues, where apoptosis is suppressed, Chk2 phosphorylates and inactivates cell cycle...

Published: 4/8/2024 | Inventor(s): Yves Pommier, Dominic Scudiero, Christopher Self, Robert Shoemaker, David Waugh, Guangtao (George) Zhang, John Cardellina, Michael Currens, Andrew Collasanti, Charles Cook, Andrew Jobson, Sudhir Kondapaka, George Lountos

Keywords(s): Anti-cancer Therapeutic, Chk2 Inhibitors, Sensitizing Agent for current DNA-damaging cancer therapeuti

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Sensitizing Cancer Cells to DNA Targeted Therapies

Published: 4/8/2024 | Inventor(s): Yves Pommier, Robert Shoemaker, Dominic Scudiero, Michael Currens, John Cardellina, Andrew Jobson

Keywords(s): Anti-cancer Therapeutic, Chk2 Inhibitors, Sensitizing Agent for current DNA-damaging cancer therapeuti

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing

Capsid-Free AAV Vectors for Gene Delivery and Their Use for Gene Therapy

The invention concerns novel capsid-free AAV vectors that can be used for gene delivery and gene therapy applications. The invention provides for a linear nucleic acid molecule comprising in this order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest, and a second AAV ITR, wherein said nucleic acid...

Published: 7/25/2024 | Inventor(s): Lina Li, Luis Garcia, Cyriaque Beley, Thomas Voit, Robert Kotin

Keywords(s): AAV, Cell, Clonal, Containing, DNA, GB2AXX, Lines, Listed LPM Reichman as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Rescueable, Sf9, STABLE, Vector, VPXXXX, WJXXXX, XEXXXX, YAXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Dental, TherapeuticArea > Endocrinology, Application > Therapeutics, TherapeuticArea > Ophthalmology, TherapeuticArea > Oncology, TherapeuticArea > Cardiology, TherapeuticArea > Infectious Disease